跳至主要内容
临床试验/NCT01042873
NCT01042873Unknown4 期

The Hemodynamic Response to Prolonged Dobutamine Infusion

Hadassah Medical Organization1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2010年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
100
试验地点
1
主要终点
Heart rate

研究概览

简要总结

A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is thought to play a major role in the pathogenesis of diseases such as congestive heart failure. However, currently, there is no in vivo model that will enable us to measure desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo.

Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1 adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic responses to dobutamine over time.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • healthy subjects

排除标准

  • consumption of any medications during the 2 weeks prior to the study
  • history of chest pain or tachycardia

研究组 & 干预措施

Intravenous dobutamine

Other

3 hours infusion of dobutamine

干预措施: 3 hours intravenous dobutamine (Drug)

结局指标

主要结局

Heart rate

时间窗: 3 hours

次要结局

  • Systolic blood pressure(3 hours)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验